CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 表达下调与 CAR-T 细胞治疗后套细胞淋巴瘤复发相关
英文原题：Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy.
查看英文原题
Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们报告一例IV期套细胞淋巴瘤患者，该患者对常规一线和二线治疗耐药，随后接受CAR-T 细胞治疗。治疗起初有效，CAR-T 细胞在体内明显扩增。然而，恶性B细胞CD19表达下调后，治疗突然失效。
展开英文摘要原文
We report the case of a stage 4 mantle cell lymphoma patient, resistant to conventional first- and second-line therapies, treated with CAR-T cells. The therapy was initially efficacious, with an appreciable CAR-T cells expansion in vivo. However, downregulation of CD19 expression on malignant B cells led to sudden therapy failure.
论文信息
- 作者
- Peruzzi B、Mazzoni A、Cutini I、Matani F、Caporale R、Bencini S、Pratesi S、Maggi L
- 单位
- Flow Cytometry and Immunology Diagnostic Unit, Careggi University Hospital, Florence, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- European journal of immunology2026 Jan
- 原文标识
- PubMed 41574447 · DOI 10.1002/eji.70123